bavituximab + temozolomide

Bavituximab + temozolomide is an investigational combination therapy studied primarily for the treatment of newly diagnosed glioblastoma. Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS) on tumor endothelial cells, leading to immune activation against tumor cells and anti-angiogenic effects. Temozolomide is an oral alkylating agent that induces DNA damage and cell death in rapidly dividing cancer cells. The combination has been evaluated alongside standard-of-care radiation therapy, with clinical data suggesting potential synergistic effects—bavituximab modulates the immunosuppressive tumor microenvironment while temozolomide provides cytotoxic activity[5][7][8]. Clinical trials have shown promising results in terms of overall survival and progression-free survival compared to historical benchmarks for glioblastoma[5][8].